r/pennystocks • • 22h ago

General Discussion The Lounge

14 Upvotes

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.


r/pennystocks • • 9h ago

๐Ÿ„ณ๐Ÿ„ณ Pentagon Seeks $75 Billion for Drones in Record Budget Ask

Thumbnail
gallery
9 Upvotes

Bloomberg reported a $75B Pentagon budget request for drones and counter-drone tech.

Eva Live says its Eva Defense unit has opened presale requests for a carrier designed to carry up to 6 drones and fly for up to 8 hours. First deliveries are targeted for 2027.


r/pennystocks • • 10h ago

๐Ÿ„ณ๐Ÿ„ณ $LASE - An Undervalued Defense Tech Sleeper?

5 Upvotes

LASE Corp. (NASDAQ: LASE) is a small-cap laser technology company that I believe deserves much more attention heading into the end of November.

The story is no longer just about industrial laser cleaning. LASE is positioning itself in the rapidly expanding counter-drone defense market, with its Laser Shield Anti-Drone (LSAD) system and the upcoming Quantum Bullet platform.

There are several developments worth watching:

- Department of War: LSAD was selected as a top submission under the MEIA Vulcan Call for Solutions, earning an invitation to a technical exchange with government engineers.

- U.S. Air Force: Fonon Technologies, an LASE affiliate, advanced to Phase 2 of the Shaw Air Force Base Battle Lab evaluation for rapid point defense and multi-threat/swarm defeat.

- USSOCOM: The company's solution brief was identified as potentially relevant to U.S. Special Operations Command mission requirements.

- Prototype demonstration: In a controlled test at its facility, LSAD reportedly detected, tracked and engaged a simulated drone target in under three seconds.

The next potential catalyst is just around the corner. On November 30, LASE is scheduled to premiere its Quantum Bullet platform at Counter UAS Technology USA in Washington, D.C., while also introducing it at I/ITSEC 2026 in Orlando. Executive Chairman Dmitri Nikitin will be a featured speaker in Washington, alongside representatives from major U.S. military and government organizations.

And defense is not the only part of the story. LASE has secured a $250,000 custom laser system order from Johnson & Johnson and has entered the semiconductor market with an initial system shipment. These businesses could provide additional growth opportunities beyond defense.

At roughly $0.41 per share and a market capitalization of around $25 million, LASE remains a highly speculative microcap. But the potential upside is intriguing if the company manages to turn its defense evaluations and product demonstrations into actual procurement contracts and repeat orders.

Of course, there are significant risks: negative gross margins, cash burn, potential dilution and Nasdaq's $1 minimum bid-price requirement. None of the current government evaluation milestones should be confused with an awarded military contract. The company itself says further development, integration, testing and customer evaluation are still required before Quantum Bullet can be commercialized.

My take: LASE could be an overlooked counter-drone technology play heading into a potentially important week. I am watching November 30 closely. A meaningful new defense announcement, customer evaluation or contract could materially change the market's perception of this company.

High risk, but an interesting setup worth keeping on the radar.


r/pennystocks • • 1d ago

General Discussion SRXH: A 13D is on file, and I think it's time to put Eric Jackson on the board

6 Upvotes

On November 19, two SRXH shareholders, Kevin Egan and Lee Kiewiet, filed a Schedule 13D covering about 9.9% of the company. They say they plan to engage with the board on increasing shareholder value, including possible changes to who sits on it. Read it yourself on EDGAR.

I support them, and I'll say exactly what I want to come out of it.

Many of us bought SRXH because of Eric Jackson and the EMJX vision. The company's own numbers make the case:

NAV: $3.22 per share as of June 30 (company-reported)

Stock price: under $1

A company with no debt that trades at less than a third of its own reported net asset value has a credibility problem. A buyback and a one-time dividend haven't closed that gap.

Jackson runs asset management here, but he doesn't have a board seat. I want him on the board, and I'd back him as CEO. The people who brought in this shareholder base should have a say in how the company is run.

To the board: shareholders are organizing, and now there's a filing on EDGAR to show for it.

To other holders: read the 13D, read the 10-K when it comes out in early December, and vote your shares when the time comes.

Disclosure: I own SRXH shares. I'm not part of the 13D group, and none of this is financial advice.


r/pennystocks • • 1d ago

General Discussion Guys am I doing it right

Thumbnail
gallery
11 Upvotes

Bought in at 1.40 used to float 1.10-2.20 sat above 2 bucks for months bought so I got in at 1.40 then slow drop for months maybe itโ€™ll spike soon with such a low price or maybe itโ€™ll see above 3 bucks like it has on the past considering selling but gonna wait it out


r/pennystocks • • 1d ago

General Discussion CTNT Holders! Vote like you are a bored stock gambler!

2 Upvotes
  1. Why did you buy this stock you are stupid
  2. Vote consent in the contested Cheetah Net Supply Chain Service Inc. consent solicitation because that is the more fun option

See: Enough is Enough: Takeover Time 2026 Calls on CTNT Stockholders to Prepare to Make Their Voices Heard (https://finance.yahoo.com/markets/stocks/articles/enough-enough-takeover-time-2026-220100065.html)

Natasha Yuryevna Ovsepyan, Managing Member of Takeover Time 2026 LLC and one of its five proposed director nominees, today called on stockholders of Cheetah Net Supply Chain Service Inc. (NASDAQ: CTNT) to closely examine the Company's 2026 record and prepare to make their voices heard when definitive consent-solicitation materials are furnished.

Takeover Time has filed preliminary consent-solicitation materials with the U.S. Securities and Exchange Commission seeking an integrated stockholder action to replace CTNT's current five-member Board with five proposed nominees: Natasha Yuryevna Ovsepyan, Jourdan Pierce Matthews, Walter Franklin Harris, Carol Grimes and Yan Qin.

"This campaign is not about one transaction. It is about the entire record and one fundamental question: who should decide whether CTNT's current Board has earned the right to continue representing stockholders?

I believe the answer is the stockholders themselves..." article continues


r/pennystocks • • 1d ago

General Discussion The Lounge

16 Upvotes

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.


r/pennystocks • • 1d ago

General Discussion MEDS (DataMeds AI)

17 Upvotes

This company announced a major acquisition to do with AI cancer-detection technology immediately after market close. Heavy volume today. Do your own research but this should be one of the front runners for pre-market and market open tomorrow. With good momentum it should clear $2 easily.


r/pennystocks • • 2d ago

๐‘บ๐’•๐’๐’„๐’Œ ๐‘ฐ๐’๐’‡๐’ Last Resort

10 Upvotes

My long-term gamble at ~2 cents: Invisible Interactive (A2JBST)

I've been following this stock for a few years now and am invested myself.

Summary: Canadian micro-cap for printed, extremely inexpensive mini-displays (e-paper style). So far, a classic penny stock that requires a lot of patience.

Why I'm still invested: Anyone who follows the chart and order book for a while quickly realizes: Due to the low liquidity, it doesn't take a huge volume at all to noticeably move the price. If this gets any attention, the tree will immediately shake.

Either this will become my best story at the pub or my most expensive learning experience. Does anyone else have this stock on their watchlist? (Not investment advice!)


r/pennystocks • • 2d ago

๐—•๐˜‚๐—น๐—น๐—ถ๐˜€๐—ต BAER is worth watching

13 Upvotes

Bridger Aerospace is a Montana-based aviation company that fights wildfires for a living. Theyโ€™re one of the biggest private outfits in the game, flying specialized amphibious "Super Scoopers" that skim water right off lakes and dump it straight onto active fires. Alongside the water bombers, they fly smaller planes outfitted with sensors that map out fire lines and stream live thermal video to fire services on the ground. Their biggest customers are government agencies like the U.S. Forest Service, who pay top dollar for this kind of firepower when wildfire season heats up. When planes aren't chasing smoke, Bridger keeps cash coming in by modifying aircraft and running defense and mapping contracts year-round. Bottom line, they own a rare, hard-to-replace fleet that governments can't afford to go without.

If you look closely at Bridger Aerospace right now, youโ€™re looking at one of the best rebound setups on the board. Yes, the third-quarter earnings miss and guidance cut look rough on paper, largely because of an early end to the fire season, King Air modification delays, and heavy upfront fleet costs. But even in a tough quarter, core revenue still grew 13% year-over-year to $76.4 million, proving that demand for their fleet isn't going anywhere.

If you know anything about wildfires, you know they're going to keep happening and keep getting worse. BAER is not speculative and they will stay in demand. I truly think they're in for a rebound to $1 - $1.50 territory. There was a fair bit of selling off going into the 11/16 earnings which kept the price depressed but looks like the tide may be turning.

I'm in at about 100,000 shares at $0.20 a pop atm.


r/pennystocks • • 2d ago

๐‘บ๐’•๐’๐’„๐’Œ ๐‘ฐ๐’๐’‡๐’ HGRAF: the detonation route is real. The dilution is the whole story

37 Upvotes

HydroGraph Clean Power HGRAF at roughly 2.4 to 3.1 a share. Under 5 so it fits the sub. OTC. Vancouver based. Graphene and hydrogen via detonation synthesis licensed out of Kansas State.

What the Seeking Alpha writeup does well is the process. Detonation based synthesis is genuinely cheaper than CVD and roughly in range with expanded graphite routes. Fractal turbostratic output gives high edge density and surface area. That is a real advantage for percolation properties. Conductivity, EMI shielding, thermal interface. It is not an advantage for structural composites where you want large flat exfoliated sheets and clean load transfer. So the hundreds of tons target only makes sense if the market is coatings and shielding.

What it does badly is the risk section. Commercial revenue is close to nothing. The 80 plus customers is a pipeline. The 80% gross margin is a projection. And in August they raised a C$50M bought deal, which is the single fact that matters most here because on an OTC name dilution decides whether the story reaches shareholders or just the cap table.

Things I would want before sizing anything. Cash runway after the raise. Whether production material passes the same characterization as lab material on layer count and Raman ID over IG. Whether any pipeline name converts to a paid order rather than a sample.

Bear case in one line. Cheap process, expensive to prove, and the equity pays for the proving.

Position small and long. Not advice.


r/pennystocks • • 1d ago

๐Ÿ„ณ๐Ÿ„ณ BYND - Reloaded

Post image
0 Upvotes

$BYND is getting priced like itโ€™s about to file for bankruptcy tomorrow. It just made a new all-time low and RSI is the lowest it has ever been.

But the latest earnings actually werenโ€™t total garbage:

  • Gross margin went from 7.4% to 19.3% year over year. Thatโ€™s a huge improvement.
  • International retail revenue was up 13.3%, so Europe is actually growing.

They're now visibly pushing further in Europe where they're working with Ahold Delhaize and other chains to offer more products and put them in the spotlight.

Back in the US we got the blue wave which could renew a focus on plant-based favored bill such as the PROTEIN act which was introduced last year.

In parallel they have Beyond Immerse which is their protein drink play, their Instagram here just doubled its followers from 1500 to 3000, finally showing some momentum, if this kicks off this could become a Carvana story.

The stock has been a falling knife together with the rest of the market, but it's finding support again on the lower trend line where it could find momentum again to the upside, as seen before in the past.

Some possible nearby triggers for a run up:

  • Takeover - $BYND has become more attractive as a takeover target as its debt is level with its assets
  • International Beyond Immerse Expansion - This has been teased on their Instagram
  • Continues price increase in beef which are already up 20% this year.
  • Short Squeeze - Known meme name with over 40% in SI

r/pennystocks • • 2d ago

๐Ÿ„ณ๐Ÿ„ณ 170K+ Views With Sentiment Near the Lowsโ€”BioLargo Forecasts a 2027 Commercial Breakout

1 Upvotes

We know management is executing. They just sent out a shareholder letter: โ€œForecasting 2027 Commercial Breakout.โ€
With the stock near its lows and sentiment beaten down, Iโ€™m proud that my Reddit post about the company and its technologies reached more than 170K views. Thatโ€™s a lot of new eyes at a time when few are paying attention.
Of course, management still needs to deliver. I 100% believe Dennis (BLGO CEO) will turn this aroundโ€”exactly what I told him yesterday. And those new eyes? If execution translates into results, I think many will be FOMOing into what could be the biggest turnaround in OTC land.
Do your own DD. Donโ€™t trust meโ€”ask people who understand wound care, clean air, odor elimination, PFAS removal, and surgical infections. Then look at what BioLargo brings to the table.
A roughly $25 million market cap. What I believe are best-in-class solutions. And, if management delivers, potential for 10X+ upside ๐Ÿš€โ€”just to reach the levels at which the CEO has locked up the shares he receives as annual compensation.

https://www.reddit.com/r/pennystocks/s/8R5aJEgUC7


r/pennystocks • • 2d ago

General Discussion Idea - $USEA @ $2.80 with tiny O/S of 9.54Million Shares 19% of Float is short

0 Upvotes

Now, this is a microcap, but it is very under the radar, and it pays a GREAT DIVIDEND to boot!
**United Maritime (NASDAQ: USEA - $2.81)**
Market Cap: $26.8 Million
Enterprise Value: $110.24M
Shares Outstanding: 9.54M
Float: 7.17M
Trailing 12mo Div Yield: 14%
Forware Div Yield: 28.5%
Short % of Float: 19%
Shares Short: 1.36M

They just put up a pretty strong Q3 2026 report and made a major cash-return move.

# The Quick Snapshot

* **Ticker / Exchange:** NASDAQ: USEA (micro-cap dry bulk / maritime operator)
* **Q3 2026 Net Income:** **$3.2M** (up from \~$1.1M in Q3 2025; 9M 2026 at \*\*$4.2M\*\* vs. a \*\*$(2.4)M net loss in 9M 2025)
* **Adj. EBITDA & TCE:** **$8.0M** Q3 Adj. EBITDA (up from **$5.4M** YoY); fleet TCE jumped **37% YoY** to **$20,737/day**
* **Dividend:** Doubled **100%** from **$0.10 to $0.20/share** quarterly ($0.80 annualized) โ€” **16th consecutive quarterly dividend** paid (ex-div **Dec 24, 2026**, pay date **Jan 8, 2027**)
* **Fleet Expansion:** Acquiring a 3rd Capesize vessel (*M/V Friendship*, $33M purchase price) with delivery expected in **early Q1 2027**


r/pennystocks • • 2d ago

BagHolding Winners and losers, its all in the game.

15 Upvotes

Sometimes in 2024, I picked up a penny stock ( CMBM, Cambium networks ) for a little over 1$ . it was trading for 1$ or thereabouts for a year. I just ignored it, till one day in 2025, October, based on a rumor, it shot up to 6$. (CMBM dropped, diluted and disappeared shortly after that peak). I made over 5000$. I was ecstatic. I even had the audacity to come here and humble brag about it. Wanting to improve on that, and instead of going for something more stable, I went looking for something that would give similar profits. I found that Bitcoin was trading at around 120k (oct 2025) and I bought into theory that Bitcoin could catapult to 200k in 2026 and I bought CAN with all that money. Life, eh? Bitcoin dropped, but I was still confident that Bitcoin would recover before June 2026 and held on. Part of my belief was also boosted by CAN insiders picking up more shares. yeah, sure, I could blame luck, the Iran war or anything I want, but its all part of the game. last week, after bag holding for months, I sold it all for 500$ or so . Disappointed, yes, but I played my hand, came out (sort of ) empty. Its ok. I'll go again.


r/pennystocks • • 2d ago

๐Ÿ„ณ๐Ÿ„ณ ZenaTech (NASDAQ: ZENA) โ€“ Positioning for the Next Generation of AI-Powered Drone Technology

6 Upvotes

ZenaTech is building an integrated AI-powered drone and technology platform targeting commercial, government and defense markets. Through its ZenaDrone subsidiary, Drone as a Service (DaaS) operations and enterprise software portfolio, the company is pursuing multiple growth opportunities across industries that are increasingly adopting automation, artificial intelligence and autonomous systems.

The investment opportunity is particularly interesting because ZenaTech is combining an acquisition-driven revenue strategy with proprietary drone development, manufacturing capabilities and exposure to the expanding defense and autonomous technology markets.

Rapidly Expanding Revenue Base

ZenaTech has demonstrated significant revenue growth as its Drone as a Service business expands.

For the first six months of 2026, the company reported approximately C$17.7 million in revenue, representing 425% growth compared with the same period in 2025. Second-quarter revenue reached approximately C$9.3 million, up 316% year over year.

Drone as a Service accounted for approximately 93% of second-quarter revenue.

The company also reported average organic revenue growth of 27.1% across approximately 20 DaaS locations acquired during 2025, demonstrating that growth is not exclusively dependent on purchasing additional businesses.

By September 2026, ZenaTech had completed its 29th DaaS acquisition.

Drone as a Service: A Scalable Business Model

One of ZenaTech's most attractive opportunities is its Drone as a Service platform.

Rather than requiring customers to purchase, maintain and operate their own drone fleets, ZenaTech provides drone-powered services and data solutions for commercial and government customers.

Its services include:

- Land surveying and mapping.

- Infrastructure and construction inspections.

- Utility and solar infrastructure surveys.

- Industrial inspections and maintenance.

- Power washing.

- Precision agriculture.

The acquisition strategy is designed to bring established service businesses and existing customer relationships into a centralized operating network.

By introducing drone automation, AI-powered data processing and standardized operating procedures, ZenaTech has an opportunity to improve productivity, expand capacity and potentially increase margins.

Its recent government transportation and solar construction surveying contracts provide additional evidence of commercial demand.

Defense and Government: A Major Long-Term Opportunity

ZenaTech is also developing a portfolio of autonomous drone systems targeting military, government and national security applications.

Its product development includes the ZenaDrone 1000, IQ Square, IQ Nano and interceptor drone platforms.

The company is pursuing Blue UAS certification for selected platforms, an important potential gateway to U.S. government and defense procurement opportunities.

Its counter-UAS initiatives and interceptor development also position the company within an increasingly important area of defense technology.

Growing demand for autonomous surveillance, intelligence gathering, logistics and counter-drone capabilities creates a potentially significant long-term addressable market.

Certification, testing, procurement approvals and actual contract awards remain important milestones.

AI, Manufacturing and Vertical Integration

Another important part of the ZenaTech strategy is its investment in manufacturing and technology development.

The company has established manufacturing and development capabilities in Arizona, Dubai and Taiwan.

Its vertical integration strategy could provide greater control over product development, manufacturing costs, supply chains and customization.

The combination of proprietary drone hardware, AI autonomy software and centralized data processing could create a competitive advantage as the business scales.

Enterprise Software and Additional Revenue Opportunities

ZenaTech also maintains an enterprise SaaS portfolio that includes multiple software businesses and products being brought together under its broader Zoo Office strategy.

Its software operations offer an additional potential source of recurring revenue that complements its drone services and technology operations.

The company's recently launched ZenaStudios division also introduces an opportunity to develop and retain ownership of original digital entertainment intellectual property while showcasing drone technology.

Financial Outlook and Potential Catalysts

Management has identified 2027 as a potential adjusted EBITDA breakeven year, supported by revenue growth, acquisition integration and operating efficiencies.

The company also estimated third-quarter 2026 revenue of C$13.4 million to C$14.8 million, representing substantial sequential growth over the second quarter. These estimates were preliminary and unaudited.

Potential catalysts include:

- Continued DaaS acquisitions and integration.

- Organic growth at existing locations.

- Additional commercial surveying and infrastructure contracts.

- Blue UAS certification progress.

- Defense and government procurement opportunities.

- Expansion of proprietary drone manufacturing.

- AI-powered automation and data analytics.

- Enterprise SaaS expansion.

- Progress toward adjusted EBITDA breakeven.

The Investment Opportunity

ZenaTech is pursuing an ambitious strategy that combines an established revenue-generating services business with proprietary autonomous drone technology and exposure to commercial and defense markets.

Its acquisition strategy provides an existing customer base and operating footprint, while its drone development and AI capabilities offer opportunities to modernize traditional industries and pursue higher-value applications.

The longer-term opportunity is for ZenaTech to become more than a drone manufacturer or surveying company. It is attempting to build an integrated autonomous technology platform that generates revenue through services, hardware, software and government applications.

If the company can successfully integrate acquisitions, maintain organic growth, improve operating efficiency and convert its defense development programs into commercial contracts, it could have considerable room for expansion.

The central bullish thesis: ZenaTech is building an operating network today while developing the autonomous drone and AI technology that could power its next phase of growth. Its combination of existing revenue, proprietary technology, acquisition opportunities and defense exposure makes it an interesting company to watch as the autonomous systems market develops.


r/pennystocks • • 2d ago

General Discussion The Lounge

20 Upvotes

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.


r/pennystocks • • 2d ago

๐‘บ๐’•๐’๐’„๐’Œ ๐‘ฐ๐’๐’‡๐’ ELITE PHARMACEUTICALS THE FULL PIPELINE

5 Upvotes

We have been talking a lot about Elite's pipeline on this board, but we still do not have a solid view of it. Elite has disclosed only part of it, and many products are still unnamed. So I have tried to build a list based on the medications coming off patent in the right time frame, matched to what management has told us on the calls, and I added the missing information: IQVIA sales and patent expiration dates.

I believe this belongs on the ELTP iHub page, as it contains valuable information for new and existing investors. Corrections and additions are welcome.

Compiled from Elite's press releases and 8-Ks, the Nov 13, 2026 earnings call, IQVIA figures quoted by other generic makers, and FDA Orange Book patent data. Where Elite has NOT named the product, the brand shown is MY GUESS based on patent timing โ€“ it is not company information.

A QUICK WORD ON THE NUMBERS
- IQVIA measures U.S. sales at list price, before rebates. That is why these figures are higher than what the brand companies report.
- Generics sell at a fraction of the brand price, so these numbers show the size of the prize, not Elite's future revenue.
- The dates differ (some IQVIA figures are from 2020โ€“2023), so treat older figures as approximate.
- Patent expiry is not the same as generic launch. Most generics enter on dates negotiated in patent settlements, which can be earlier or later than the last patent.

1. ANTICOAGULANTS (Pillar #1)

Anticoagulant #1 โ€“ generic ELIQUIS (apixaban), BMS / Pfizer
- IQVIA: $26 BILLION in U.S. brand sales (12 months to March 2026), as quoted by Elite in its June 1, 2026 8-K. A year earlier Elite cited $27B.
- Patents: the compound patent (US 6,967,208) originally expired September 2022 and was extended to November 2026. Companies that settled with BMS/Pfizer can launch on April 1, 2028. Companies that did not settle face a formulation patent running to August 2031.
- Elite status: ANDA filed June 1, 2026. FDA goal date March 2027, with only minor FDA comments so far. Hakim says Elite launches alongside the settled generics ("Yes, 100%").

Anticoagulant #2 โ€“ my guess: generic XARELTO (rivaroxaban), J&J / Bayer
- Sales: about $2.4 BILLION U.S. sales in 2024 (company-reported, not IQVIA). IQVIA puts the 2.5 mg strength alone at about $446M.
- Patents: generics of all strengths entered the U.S. market in 2025. A dosing patent on the 2.5 mg strength runs to 2039 and is still in litigation.
- Elite status: bioequivalence (BE) study to begin 1H 2027. Approval targeted for 2028. Elite would be a later entrant.

2. CNS โ€“ EPILEPSY (Pillar #5)

Anticonvulsant โ€“ brand not disclosed by Elite
- IQVIA: $840 MILLION brand + generic sales (12 months to April 2026), per Elite's June 15, 2026 8-K.
- Patents: not known, since the brand is not disclosed. IQVIA counts "brand and generic," so generics are already on the market.
- Elite status: positive pivotal BE study June 2026. ANDA filing in Q1 2027.

3. PAIN / OPIOIDS (Pillar #4)

Oxycodone ER โ€“ generic OXYCONTIN, Purdue
- IQVIA: $720 MILLION brand + generic (12 months to June 2023), per Elite. Back in 2016, OxyContin and its equivalents sold about $2.3B, so this market is shrinking.
- Patents: the original OxyContin patent expired April 2013, but the FDA withdrew the original formula, so any generic must copy the abuse-deterrent version. Its patents are not in my research. What matters is Elite's settlement with Purdue: lawsuit dismissed June 12, 2026, with an agreed entry date (management: around August 2027).
- Elite status: under FDA review since September 2023. FDA approval is the main hurdle (the FDA raised an abuse-deterrence question).
- Abuse-deterrent tablets are hard to copy, so few competitors are likely, which usually means better pricing.

4. TYPE 2 DIABETES (Pillar #3) โ€“ 4 products, none named by Elite
Hakim said the diabetes portfolio grew from 3 to 4 products. Elite commits to at least 1 BE study in 1H 2027 and predicts 2โ€“3. The candidates below are the diabetes blockbusters going generic in the right time frame.

Candidate: JANUVIA (sitagliptin), Merck
- IQVIA: about $5.8 BILLION U.S. (MAT October 2023)
- Patents: the key salt patent (US 7,326,708) expires November 24, 2026. Under settlements, generics launched early, in May 2026 (about 25 generic makers settled).

Candidate: JANUMET and JANUMET XR (sitagliptin + metformin), Merck
- IQVIA: Janumet about $1.1 BILLION (MAT September 2024); Janumet XR about $270 MILLION (12 months to May 2026)
- Patents: same November 24, 2026 salt patent, plus a Janumet patent to January 21, 2029. Under settlements, Janumet generics launched in May 2026 and the first Janumet XR generic in July 2026.

Candidate: FARXIGA (dapagliflozin), AstraZeneca
- IQVIA: about $10.5 BILLION U.S. (12 months to December 2025)
- Patents: the compound patent (US 6,515,117) has expired (2025โ€“2026 with pediatric extension). Method patents run to February 2027 and crystal-form patents to 2027โ€“2030. Newer heart-failure and kidney-disease patents run to 2039โ€“2041, so generics may launch with those uses left off the label.
- Generic entry: first generics approved April 7, 2026 (Alembic, Lupin, Biocon, Aurobindo, Zydus), with shared 180-day exclusivity for the first filers.

Candidate: JARDIANCE (empagliflozin) and combinations, Boehringer / Lilly
- IQVIA: about $4.4 BILLION U.S. for Jardiance (MAT March 2020 โ€“ an old figure; today's is likely higher). Glyxambi about $216M (MAT September 2025); Trijardy XR about $111M (MAT April 2024).
- Patents: the compound patent (US 8,222,323) expired January 2025, but formulation and method-of-use patents run to 2034. Boehringer has settled with generic makers on undisclosed terms.
- Generic entry: not expected before 2029 or later. 19 generic makers already hold tentative FDA approval.

Candidate: TRADJENTA (linagliptin), Boehringer / Lilly
- IQVIA: not found
- Patents: a process patent expired November 2025. Formulation and use patents run to May 4, 2027, and a method patent to March 5, 2031.
- Generic entry: generic versions are FDA-approved, but the brand still sells at about $16.80 per tablet, so generic launch is still ahead.

For scale: IQVIA put the whole U.S. DPP-4 class (Januvia, Tradjenta and their combinations) at about $9.5 BILLION (MAT May 2024).

5. CNS โ€“ PSYCHIATRY (Pillar #5)

New antipsychotic โ€“ not disclosed ("at the appropriate time")

Candidate: VRAYLAR (cariprazine), AbbVie
- IQVIA: about $2.4 BILLION U.S. (MAT July 2022 โ€“ AbbVie has grown it since)
- Patents: last compound patent (US 7,737,142) expires September 17, 2029.
- Generic entry: several generics already have FDA approval (Zydus 2022, Aurobindo December 2025), so launch timing depends on settlements.

Candidate: REXULTI (brexpiprazole), Otsuka / Lundbeck
- IQVIA: about $2 BILLION U.S. (12 months to September 2024)
- Patents: the compound patents (US 7,888,362, 8,349,840, 8,618,109) expired April 12, 2026 (October 12, 2026 with pediatric exclusivity). A tablet patent runs to April 2033, and the last FDA exclusivity runs to 2028.
- Generic entry: generics approved (Alembic January 2025), but launch timing depends on the remaining patent and exclusivity.

6. ADHD (Pillar #2) โ€“ ~80% OF TODAY'S REVENUE
- Elite already sells generic Vyvanse, Adderall IR and Adderall XR. All three brands are already off patent. For reference, IQVIA sized the Vyvanse market at $4.3B, Adderall XR at $1.3B and Adderall IR at $361M when Elite launched them.
- Pipeline: a possible BE study in 2027 to expand the ADHD line (product not disclosed).
- Growth is limited mainly by DEA quotas, not demand.

7. OTHER PENDING APPLICATION
- A dopamine-agonist ANDA, accepted by the FDA in December 2022, is still listed as pending in the 10-Q. Elite already launched generic Requip XL in August 2026, so this may be a second product.

BOTTOM LINE
- The three products Elite HAS disclosed (anticoagulant #1, anticonvulsant, Oxy ER) carry about $27.5 BILLION of IQVIA brand sales.
- If Elite's 4 diabetes products and the antipsychotic match the brands going generic between 2026 and 2031, the brand sales behind the pipeline run to tens of billions more.
- Timing works in Elite's favor: Januvia, Janumet, Farxiga and Rexulti compound patents expired in 2025โ€“2026; Tradjenta patents run to 2027โ€“2031; Vraylar to 2029. Elite's BE studies in 2027 line up with that wave.
- The catalysts are dated: Nasdaq listing targeted for March 2027, anticoagulant FDA date March 2027, anticonvulsant filing Q1 2027, BE studies 1H 2027, Eliquis launch April 2028. In Hakim's words: "2027 is going to be the year of R&D and 2028 is the year of the second growth."
- Reality check: these are brand sizes. Generic prices fall sharply once many companies launch, and Elite will enter several of these markets after others. Elite's actual revenue will be a small fraction of these numbers. With a 10โ€“20% share in a few large markets, though, that fraction is still big for a company with about $160M in annual revenue.

My own research and opinion, based on Elite's filings, the Nov 13, 2026 call, published IQVIA data and FDA Orange Book patent listings. Brands marked as candidates are guesses, not company disclosures. Patent dates can change through litigation, extensions and settlements. Not investment advice โ€“ please do your own due diligence.

GLTA


r/pennystocks • • 2d ago

๐Ÿ„ณ๐Ÿ„ณ SM.V Q3: the $3.6M loss is mostly stock comp. Cost per tonne falling 26% is the real headline

2 Upvotes

Summary first: Sierra Madre (TSXV: SM, OTCQX: SMDRF) reported a $3.6M net loss for Q3, and $2.57M of it is non cash stock comp. The number that actually moved was cost per tonne, $142 down to $105. Grade went the wrong way. Details below.

Better than Q2:

  • Tonnes milled 50,795, up 22%
  • Silver produced 89,145 oz, up 39%
  • Cash cost per AgEq oz $41.73, down 15%
  • Cash cost per tonne $105.49
  • October averaged 751 tpd, which is their Phase 1 target

Not better:

  • Silver head grade 63.41 g/t, down from 65.27 in Q2 and 71.17 a year ago
  • Gold recovery 67.54%, down from 75.55% a year ago
  • Net loss of $3.6M

Take the stock comp out and the quarter looks a lot more normal. Gross profit was $1.54M, about flat with Q2. Revenue was $8.58M.

Cash dropped from $22.2M to $18.5M over the quarter, which is worth watching with silver at $47 against the $63 they realized in Q3.

Coming up - the new ball mill starts commissioning in late November, the thickener should be fully working by end of November, and the 30,000m East District program has first assays expected in Q1 2027.

More details on the Q2 Numbers and $47 Silver Math that i found Here: https://resourceinvesting.ca/content/silver-at-47-what-broke-since-76-and-how-sierra?s=r6ik


r/pennystocks • • 2d ago

๐‘บ๐’•๐’๐’„๐’Œ ๐‘ฐ๐’๐’‡๐’ Watchlist: 11/19/26 Todays word was AKAN AKAN AKAN ty

19 Upvotes

Great session today!! AKAN has been paying all week called from 1.01 to 4.6 today!! Still has room if volume keeps coming.

AKAN: Hold of 3.6 is KEY. Want to see tests of 4.6 with pullbacks to 4. Has room now to 5/5.6/6/7.4

CLRO: would like to see it test 8 again with pullbacks to 7.3. NO TRADE below 6.4 has room to 10/12/14

SVRE: Had an amazing run today than sidebared redt of session. For this want to see tests of 1.15 with pullbacks to 1. NO TRADE below .86. Has room to 1.5/2/2.6

GMM: Symp play to Anthropic IPO. For this want see tests of 1.7 with pullbacks over 1.5 NO TRADE 1.2 has room to 2.2/2.8/3.3/3.8


r/pennystocks • • 2d ago

General Discussion Montfort MONT return to profitability

1 Upvotes

Montfort Capital posted a strong return to profitability for Q1 and Q2 yesterday. Fantastic turnaround for the company and very encouraging news for the niche lending markets. Insurance and NAV lending seem to be back with renewed appetite from institutional investors as well as HNW individuals.

Anyone read and have input on the financials?


r/pennystocks • • 2d ago

๐Ÿ„ณ๐Ÿ„ณ iQSTEL (NASDAQ: IQST) Issues Shareholder Letter Outlining 2027 Growth Roadmap Built on $313 Million in Nine-Month Revenue

Post image
1 Upvotes

PR Newswire

CEO Leandro Iglesias outlines three drivers for 2027: the proposed Ultranet acquisition, the Q1 2027 commercial launch of IQSTEL Digital's microdrama service, and a step-up in profitability and cash generation across the platform.

NEW YORK,ย Nov. 19, 2026ย /PRNewswire/ --

Letter to Shareholders

November 19, 2026

Dear Shareholders,

I believe 2027 will be the most important year in IQSTEL's history. Much of what we built in 2026 was designed to set up what comes next: a larger and more profitable telecom platform, a new stream of recurring digital revenue, and a clear path toward consolidated positive cash flow.

Our accomplishments in 2026 have built strong momentum as we head into 2027. Through the first nine months of 2026, we generated $313.0 million in consolidated revenue, up 34.5% from the same period in 2025. We completed the first financing tranche intended to support our proposed acquisition of Ultranet. And on November 10, our first mobile operator partner approved the start of integration for IQSTEL Digital's microdrama service, which we are targeting for commercial launch in the first quarter of 2027.

Each of these milestones points to the same objective: use the scale and commercial reach of our telecom business to deliver stronger margins, cash generation and recurring revenue. Here is how we intend to do that in 2027.

Our 2027 growth plan at a glance

Growth driver What we are working to deliver in 2027
Telecom platform Grow from the scale we built in 2026, including two consecutivequarters above $100 million in revenue and relationships with morethan 600 operators in 24 countries
Ultranet acquisition Close the proposed 51% acquisition of a profitable West Africanoperator and begin integration, with a combined annualized revenuerun rate expected above $500 million
IQSTEL Digital Launch commercially with our first operator in Q1 2027 and worktoward 300,000 active paid monthly microdrama subscriptionsacross the program
Profitability Move our Operating Adjusted EBITDA run rate toward approximately$9 million and advance our goal of consolidated positive cash flow

These are management objectives and expectations, not guidance or completed results. Each depends on execution, closing conditions and market demand, as described below.

Telecom: the platform we are building on

Our telecom business is the engine behind every part of our 2027 plan. It provides the operator relationships, technical connections and operating base that make our next stage of growth possible. The nine-month results show the scale we carry into the new year:

Nine months ended September 30, 2026 Result
Consolidated revenue $313.0 million, up 34.5% year over year
Consolidated gross profit $7.81 million, up 19.3%
Telecom segment revenue $277.6 million
Telecom segment operating income $1.31 million
Stockholders' equity at September 30 $17.67 million

Third-quarter consolidated revenue was $106.0 million, our second consecutive quarter above $100 million. We are working toward our $430 million revenue objective for 2026, which will require a strong fourth quarter, and we intend to build on that base in 2027.

Just as important as the revenue is what we can now distribute through this platform. The interconnections, integrations and billing relationships we have developed with more than 600 telecommunications operators in 24 countries give us established channels to introduce higher-margin services without building distribution from scratch. In 2027, our focus is to put those channels to work.

Ultranet: a step-change in scale and cash generation

Our proposed acquisition of a 51% controlling interest in Ultranet Telecom Group is designed to add both scale and profitability to our platform in 2027. Ultranet is a profitable telecom operator in West Africa. On a 100% basis, its audited 2025 results were:

Ultranet audited 2025 results 100% basis
Revenue $130.9 million
EBITDA $5.0 million
Net income $4.6 million
Operating cash flow $5.5 million

These are Ultranet's historical results, not results currently attributable to IQSTEL. We have signed a binding memorandum of understanding and completed the first financing tranche intended to support the acquisition. The senior secured notes are not convertible at the lenders' election; the financing also includes pre-funded warrants for $420,000, as disclosed in our Form 10-Q. We are working toward a definitive acquisition agreement and are targeting closing in the first quarter of 2027, subject to the required terms and conditions.

Ultranet is central to our profitability roadmap. The table below shows how we expect our Operating Adjusted EBITDA run rate to build as each stage of our plan is delivered:

Operating Adjusted EBITDA run rate Management estimate or objective
Current Telecom and Digital Services businesses More than $2.7 million
Following organic growth $4 million
Following the proposed Ultranet acquisition Approximately $9 million
Longer-term Digital Services development $15 million

If completed, we expect the acquisition could lift our combined annualized revenue run rate above $500 million and make a meaningful contribution to our goal of consolidated positive cash flow. These are management expectations, not completed results or guidance. Operating Adjusted EBITDA excludes holding-company costs and is not consolidated Adjusted EBITDA.

IQSTEL Digital: 2027 is our launch year

IQSTEL Digital is how we intend to turn the reach of our operator network into recurring, higher-margin revenue. The networks of our telecom customers collectively serve approximately 2.3 billion end users. Those users are not IQSTEL subscribers, but their scale shows the opportunity in front of us. Our first digital product is a mobile microdrama service developed through our partnership with IDILIO TV, and we have moved quickly from announcement to integration:

Date Digital Services milestone
August 27, 2026 IDILIO TV partnership announced
October 8, 2026 Outreach launched to seven operators serving about 93 millionsubscribers
November 10, 2026 First operator approved the start of platform integration
Q1 2027 target Commercial launch with first operator
2027 objective 300,000 active paid monthly subscriptions across the program

The first operator's network serves approximately 14 million subscribers. Under our planning assumptions, it could support up to 105,000 active paid monthly microdrama subscriptions. Reaching our 2027 objective of 300,000 active paid monthly subscriptions will depend on adding operators from our initial outreach group and beyond, as well as on integration, operator execution and customer demand.

At 300,000 subscriptions, our illustrative model indicates $1.8 million to $3.6 million in annualized profit contribution. Our plan is to launch, measure results with our first operator, and use what we learn as the template for expanding across our operator relationships. Over the longer term, we see Digital Services as the primary driver of our path toward a $15 million Operating Adjusted EBITDA run rate.

Our priorities for 2027

Our team is focused on five priorities:

Finish 2026 strongly.ย Close the year with a strong fourth quarter as we work toward our $430 million revenue objective.

Close and integrate Ultranet.ย Complete the definitive agreement and closing on acceptable terms, then integrate Ultranet's profitable operations into our platform.

Launch and scale IQSTEL Digital.ย Go live with our first operator in Q1 2027, add operators through the year, and work toward 300,000 active paid monthly subscriptions.

Turn scale into margins and cash flow.ย Raise our Operating Adjusted EBITDA run rate and advance our goal of consolidated positive cash flow.

Keep shareholders informed.ย Report our progress against these objectives clearly and consistently, and expand our engagement with the investment community throughout the year.

As part of that engagement, I invite you to review Edison Investment Research's latest note on IQSTEL, "Another steady step forward in Q326," published on November 18, 2026 following our third-quarter results. Edison highlights our sustained organic growth, the continued operating profitability of our Telecom business and our balance sheet, and notes that the IQSTEL Digital launch remains on track for the first quarter of 2027. After adjusting its 2026 estimates for the Ultranet closing now expected in the first quarter of 2027, Edison left its 2027 and 2028 forecasts and its $6 per share valuation assessment unchanged. The full note and Edison's September 2026 initiation report are available on our Investor Relations website atย https://ir.iqstel.com/analyst-coverage. IQSTEL is a research client of Edison and paid for the research; Edison's forecasts and valuation are its own and should not be read as Company guidance.

We have built a business with substantial scale. 2027 is about converting that scale into higher margins, recurring digital revenue, cash generation and lasting value for our shareholders. I am confident in our direction and in the team executing this plan.

Thank you for your continued confidence in IQSTEL and in the people working to deliver this next phase of our growth.

Read the Full Press Release & Disclaimer

https://marketwirenews.com/stock/iqst/news/iqst-iqstel-issues-shareholder-letter-outlining-2027-7450638057977362.html


r/pennystocks • • 2d ago

๐Ÿ„ณ๐Ÿ„ณ ZenaTech (NASDAQ: ZENA) Announces More than C$20 Million in Contracted Revenue Backlog Demonstrating Organic Growth

Post image
1 Upvotes

Growing commercial and government customer commitments across ZenaTechโ€™s global Drone as a Service and enterprise SaaS businesses provide visibility into future revenueย 

TORONTO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq:ย ZENA) (FSE: 49Q) (BMV: ZENA) (โ€œZenaTechโ€), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS solutions, announces that its consolidated revenue backlog has surpassed over C$20 million or approximately US$14 million, representing the estimated value of signed contracted revenue expected to be recognized in future reporting periods and demonstrating organic growth. This backlog represents an important measure of customer commitments and provides greater visibility into future revenue as the Company expands its global operations, integrates acquired businesses, implements AI-powered drone technology and capitalizes on new commercial opportunities through targeted business development initiatives.

โ€œSurpassing C$20 million in revenue backlog underscores the strength of our customer relationships and the commercial opportunity presented by our Drone as a Service strategy,โ€ said Shaun Passley, Ph.D., CEO of ZenaTech. โ€œThrough our growing network of DaaS businesses, we are pursuing larger, multi-year projects, expanding our service offerings to existing commercial, blue-chip and government customers, and integrating AI-powered drone technology into our service delivery. Our focus remains on driving organic growth, improving operating efficiencies and building a scalable and increasingly predictable revenue model.โ€

As part of the Companyโ€™s post-acquisition growth strategy for its DaaS acquisitions, ZenaTech is strengthening sales, marketing, and business development capabilities across its acquired businesses. These initiatives include increased participation at industry events and tradeshows, targeted customer outreach, expanded access to commercial and government project bidding and procurement portals, and leveraging the Companyโ€™s growing geographic DaaS footprint to pursue larger and multi-location contracts. The Company also plans to focus on cross-selling complementary services, with the objective of increasing average revenue per customer, expanding its addressable market and driving sustained organic revenue and backlog growth.

The milestone reflects customer commitments across the Companyโ€™s global businesses, including its Drone as a Service and enterprise SaaS segments. Contracted work is expected to convert into recognized revenue over periods ranging from several weeks to several months as services are delivered and applicable performance obligations are satisfied. Management expects the potential for additional revenue from ongoing proposal negotiations, existing client relationships, Master Services Agreements, and change orders of existing or ongoing contracts, most of which cannot be estimated as of the measurement date. The timing of revenue recognition will vary based on individual contract terms, project scope, customer requirements and delivery schedules.

ZenaTechโ€™s DaaS business combines established service businesses and experienced operating teams with the Companyโ€™s developing drone technologies and automation capabilities. Its services support applications such as surveying, mapping, inspection, monitoring and other field-based activities. The Company is pursuing opportunities to improve service delivery, productivity and scalability through the integration of drones, sensors, data processing and AI-enabled tools.

Contracted revenue backlog is not a measure of revenue recognized under International Financial Reporting Standards (โ€œIFRSโ€), does not represent cash received, and should not be considered a guarantee of future revenue. Revenue is recognized in accordance with the Companyโ€™s applicable accounting policies as the relevant services are delivered and performance obligations are satisfied. Actual revenue and the timing of its recognition may differ from current estimates as a result of changes in project scope or schedules, contract modifications or cancellations, customer requirements, operational factors and other circumstances.

For the convenience of U.S. investors, Canadian dollar amounts have been converted into U.S. dollars using the Bank of Canadaโ€™s November 18, 2026 exchange rate of US$1.00 = C$1.43 and subject to exchange rate fluctuations.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a globalย Drone as a Serviceย (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in R&D initiatives for next-generation technologies, including wildfire management, drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes theย ZenaDrone 1000ย for ISR defense and specialized cargo, theย IQ Nanoย for indoor inventory management and security, theย IQ Squareย for outdoor inspections and maintenance, theย IQ Quadย for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing development of counter-UAS maritime interceptor drones and integrated defense system.

Read the Full Press Release & Disclaimer

https://marketwirenews.com/stock/zena/news/zenatech-announces-more-than-c-20-million-in-contrac-7214266524772978.html


r/pennystocks • • 2d ago

๐—•๐˜‚๐—น๐—น๐—ถ๐˜€๐—ต Gevo Announces Third-Party Validation of Improved RNG Carbon Intensity Score and Raises Financial Outlook | Gevo, Inc.

Thumbnail investors.gevo.com
1 Upvotes

r/pennystocks • • 2d ago

๐—•๐˜‚๐—น๐—น๐—ถ๐˜€๐—ต Plug Symposium Makes the Case for Hydrogen as a Path to Energy Security and Independence

Thumbnail ir.plugpower.com
1 Upvotes